This digital product contains the six Late-Breaking science sessions presented at Heart Rhythm 2023.
The Late-Breaking Clinical Trials category includes the following sessions from Heart Rhythm 2023:
Late Breaking Clinical Trials and Science - CIED
Late Breaking Clinical Trials and Science - Registry - CIED
Late Breaking Clinical Trials and Science - Ablation
Late Breaking Clinical Trials and Science - Ventricular Arrhythmias
Late Breaking Clinical Trials and Science - AF
Late Breaking Clinical Trials and Science - Innovations
After watching a reasonable amount of Heart Rhythm 2023 On Demand - Late Breaking Clinical Trials, the learner should be able to:
Identify and analyze the latest scientific advances and innovations in the field of heart rhythm disorders.
Select appropriate, evidence-directed pharmacological and non-pharmacological therapies to achieve optimal outcomes for patients with heart rhythm disorders.
Recognize alternative perspectives regarding areas of controversy for which scientific evidence is insufficient, controversial, inconclusive, or confusing.
Utilize quality improvement measures, methods, and tools to foster systems-based improvements in heart rhythm care, outcome, and value.
Analyze and improve processes related to inter-professional teams, care coordination, patient engagement, and communication to optimize the delivery of patient- and family-centered care.
Assess the impact of regulatory and institutional policies, and societal and cultural norms, on safety, timeliness, equity (including diversity and inclusion), effectiveness, efficiency, patient-centered care, and value.
Utilize improved communication methods to engage with patients and caregivers for increased shared decision-making in the treatment of heart rhythm disorders
Evaluate the latest technology available for both professionals and consumers in the field of heart rhythm disorders.
Recognize disparities in health care and describe strategies to reduce these disparities in patient care.
Utilize shared decision-making resources in discussing monitoring and treatment of patients with heart rhythm disorders.
Describe the latest cardiac device advisories and/or recalls and explain how to share this information with patients and caregivers.
Explain the current and future trends in digital health that will impact the treatment of heart rhythm disorders.
Describe best practices for managing a device clinic, an AF center, and/or a multidisciplinary electrophysiology practice.
Learning objectives specific to the session are listed at the individual session within Heart Rhythm 2023 On Demand - Late Breaking Clinical Trials.
This activity is designed for all professionals who participate in the care and management of heart rhythm disorders.
Accreditation Statement
The Heart Rhythm Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians AMA Designation Statement
The Heart Rhythm Society designates this internet enduring activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM Maintenance of Certification (MOC) Statement
Successful completion of this ACE activity, which includes participation in the evaluation component, enables the participant to earn up to 3 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of ACE credits claimed for the activity. It is the ACE activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College of Physicians and Surgeons of Canada MOC Recognition Statement
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “ACE in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Other Credit Available
A Credit Certificate (for physicians) or Certificate of Participation (for non-physicians) will be provided to individuals seeking credit from the following organizations which accept AMA PRA Category 1 Credit(s)™. Note that participants are advised to contact their certifying body for specific information regarding credit submissions:
· American Academy of Family Physicians (AAFP) (for elective credit)
· American Academy of Nurse Practitioners Certification Board (AANPCB)
· American Academy of Physician Assistants (AAPA)
· American Nurses Credentialing Center (ANCC)
· American Osteopathic Association (AOA) (for Category 2 credit)
· Committee on Accreditation of Continuing Medical Education (Canada)
· European Board for Accreditation in Cardiology (EBAC)
· European CME Credits (ECMEC)
· German Chambers of Physicians
· National Society of Genetic Counselors (for Category 2 credit)
· Oman Medical Specialty Board
· Qatar Council for Healthcare Practitioners
· Royal College of Physicians and Surgeons of Canada (RCPSC)
Disclosure Policy
The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.
Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.
ACCME Definition:
*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Examples of such organizations include:
Advertising, marketing, or communication firms whose clients are ineligible companies
Bio-medical startups that have begun a governmental regulatory approval process
Compounding pharmacies that manufacture proprietary compounds
Device manufacturers or distributors
Diagnostic labs that sell proprietary products
Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
Manufacturers of health-related wearable products
Pharmaceutical companies or distributors
Pharmacy benefit managers
Reagent manufacturers or sellers
All relevant financial relationships have been mitigated. Individual disclosures will be shown at the session level.
For a comprehensive list of all disclosures, please visit:
Heart Rhythm 2023 Disclosures - Google Sheets